Samuel G. Johnson - Concepedia

Author

Samuel G. Johnson

Kaiser Permanente ORCID

Also Known As

Jason H. Karnes, S G Johnson, S. Johnson, Samuel G Johnson, Samuel G. Johnson, Samuel Johnson

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Kaiser Permanente University of Montana University of Colorado Denver Stanford University St. Jude Children's Research Hospital

About

Samuel G. Johnson is an author at Kaiser Permanente specializing in medicine, cardiovascular disease, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.1K
2	Public Health	5	5	941
3	Nursing	2	2	21
4	Emergency Medicine	2	2	59
5	Allied Health Professions	1	1	10

Samuel G. Johnson

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update Laura B. Ramsey, Samuel G. Johnson, Kelly E. Caudle, Clinical Pharmacology & Therapeutics Slco1b1 GenotypeLipid DisorderCardiovascular DiseaseMedicineGenetic Epidemiology	2014	437
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process Kelly E. Caudle, Teri E. Klein, James M. Hoffman, Current Drug Metabolism Genetic EpidemiologyPharmacotherapyGenetic MedicineGenotype-based Drug GuidelinesPharmacogenomics	2014	423
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy Russell A. Wilke, Laura B. Ramsey, Samuel G. Johnson, Clinical Pharmacology & Therapeutics	2012	324
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based Regimens Andrew J. Muir, Li Gong, Samuel G. Johnson, Clinical Pharmacology & Therapeutics Rbv TherapyImmunodeficienciesGenetic EpidemiologyImmunologyPharmacotherapy	2013	92
Outcomes Associated With Combined Antiplatelet and Anticoagulant Therapy Samuel G. Johnson, Kristina Rogers, Thomas Delate, CHEST Journal ThrombosisCardiovascular DiseaseCombined AntiplateletMedicineBlood Platelet	2008	80
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype John P. Clancy, Samuel G. Johnson, Sook Wah Yee, Clinical Pharmacology & Therapeutics	2014	76
Warfarin and Antiplatelet Combination Use Among Commercially Insured Patients Enrolled in an Anticoagulation Management Service Samuel G. Johnson, Daniel M. Witt, Todd R. Eddy, CHEST Journal Anticoagulation Management ServiceThrombosisPercutaneous Coronary InterventionCardiovascular DiseaseHealth Policy	2007	42
Disseminating research in rural Yup'ik communities: challenges and ethical considerations in moving from discovery to intervention development Inna Rivkin, Joseph E. Trimble, Ellen D. S. López, International Journal of Circumpolar Health	2013	28
Impact of a clinical pharmacy research team on pharmacy resident research Kari L. Olson, Adriane N. Irwin, Sarah J. Billups, American Journal of Health-System Pharmacy	2015	26
Financial Analysis of <i>CYP2C19</i> Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention Samuel G. Johnson, Don Gruntowicz, T. Chua, Journal of Managed Care & Specialty Pharmacy	2015	24

Page 1